Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Viemed Healthcare (VMD) Research & Development (2019 - 2026)

Viemed Healthcare filings provide 7 years of Research & Development readings, the most recent being $598000.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 25.53% to $598000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 1.66% decrease, with the full-year FY2025 number at $3.0 million, down 1.66% from a year prior.
  • Research & Development hit $598000.0 in Q4 2025 for Viemed Healthcare, down from $775000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $847000.0 in Q2 2025 to a low of $339000.0 in Q1 2021.
  • Median Research & Development over the past 5 years was $697000.0 (2022), compared with a mean of $683650.0.
  • Biggest five-year swings in Research & Development: surged 137.04% in 2021 and later decreased 25.53% in 2025.
  • Viemed Healthcare's Research & Development stood at $612000.0 in 2021, then increased by 17.97% to $722000.0 in 2022, then decreased by 9.83% to $651000.0 in 2023, then increased by 23.35% to $803000.0 in 2024, then decreased by 25.53% to $598000.0 in 2025.
  • The last three reported values for Research & Development were $598000.0 (Q4 2025), $775000.0 (Q3 2025), and $847000.0 (Q2 2025) per Business Quant data.